| __timestamp | Gilead Sciences, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 4167274 |
| Thursday, January 1, 2015 | 4006000000 | 5247851 |
| Friday, January 1, 2016 | 4261000000 | 4925118 |
| Sunday, January 1, 2017 | 4371000000 | 14930297 |
| Monday, January 1, 2018 | 4853000000 | 25371768 |
| Tuesday, January 1, 2019 | 4675000000 | 23921274 |
| Wednesday, January 1, 2020 | 4572000000 | 25338236 |
| Friday, January 1, 2021 | 6601000000 | 20182966 |
| Saturday, January 1, 2022 | 5657000000 | 17562000 |
| Sunday, January 1, 2023 | 6498000000 | 25212000 |
| Monday, January 1, 2024 | 28675800000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Gilead Sciences, Inc. and Pharming Group N.V. from 2014 to 2023. Over this period, Gilead Sciences consistently demonstrated a robust cost management strategy, with its cost of revenue peaking in 2021 at approximately 6.6 billion, a 74% increase from 2014. In contrast, Pharming Group N.V. showed a more modest growth, with its cost of revenue increasing by over 500% from 2014 to 2023, reaching around 25 million. This stark contrast highlights Gilead's significant scale and operational efficiency compared to Pharming's more gradual growth. As the industry evolves, these insights underscore the importance of strategic cost management in maintaining competitive advantage.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Zoetis Inc.
Gilead Sciences, Inc. vs Pharming Group N.V.: A Gross Profit Performance Breakdown
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and Pharming Group N.V.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Pharming Group N.V.
Cost of Revenue Trends: Pharming Group N.V. vs Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and Telix Pharmaceuticals Limited
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Pharming Group N.V. and Dyne Therapeutics, Inc.'s Expenses
Pharming Group N.V. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored